Asthma Endotypes in Post-9/11 Deployment-Related Asthma

Krefft, S.D.; Zell-Baran, L.; Pang, K.; Onofrei, Claudia; Kraus, Richard L.; Sharma, Sunita; Holguin, F.; Rose, C.S.

doi:10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3841

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 As both Th2-high and Th-2-low asthma endotypes are present in DRA, future drug development targeting Th2-low inflammation may benefit the DRA population. 56 Currently, there is no evidence-based treatment for DDLD. 6 Future recommendations will depend on results from larger observational and prospective trials.…”

Section: Deployment-related Respiratory Disease Krefft Zell-baranmentioning

confidence: 99%

See 1 more Smart Citation

Deployment-Related Respiratory Disease: Where Are We?

Krefft

Zell-Baran

2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Military personnel and veterans who have deployed to Afghanistan, Iraq, and parts of Southwest Asia (SWA) since 1990 are at risk of developing a host of respiratory symptoms and deployment-related respiratory diseases (DRRDs). This review aims to summarize our current understanding of DRRD and inform pulmonary practitioners of recent updates to DRRD screening, diagnosis, evaluation, and management. The most common respiratory diseases in these patients include asthma, chronic sinonasal disease, laryngeal disease/dysfunction, and distal lung disease. Pulmonary function testing and chest imaging are the most commonly used diagnostic tools, but techniques such as lung clearance index testing via multiple breath washout, forced oscillation testing/impulse oscillometry, and quantitative chest computed tomography (CT) assessment appear promising as noninvasive modalities to aid in lung disease detection in this population. We also summarize guidance on conducting an occupational and deployment exposure history as well as recommendations for testing. Finally, we discuss the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 (PACT Act) that includes a list of health conditions that are “presumptively” considered to be related to SWA military deployment toxic exposures, and provide resources for clinicians who evaluate and treat patients with DRRD.

show abstract

Section: Deployment-related Respiratory Disease Krefft Zell-baranmentioning

confidence: 99%

“…55 As both Th2-high and Th-2-low asthma endotypes are present in DRA, future drug development targeting Th2-low inflammation may benefit the DRA population. 56…”

Section: Clinical Approach To Diagnosis and Managementmentioning

confidence: 99%

Deployment-Related Respiratory Disease: Where Are We?

Krefft

Zell-Baran

2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…7 Another emerging area in occupational respiratory disease focuses on the inhalational hazards and adverse outcomes in military veterans who deployed to Southwest Asia, reviewed by Krefft and Zell-Baran. 8 New exposures often occur as new industries develop. An example is the cannabis industry in the United States which has exploded over recent years.…”

mentioning

confidence: 99%